Appointment of Nominated Adviser and Joint Broker, Clinigen Group plc, 2020-05-01






RNS Number : 5782L
Clinigen Group plc
01 May 2020
 

1 May 2020 

 

Appointment of Nominated Adviser and Joint Broker

 

Clinigen Group plc (AIM: CLIN, “Clinigen” or the “Company”), the global pharmaceutical and services company, has appointed J.P.Morgan Cazenove as Nominated Adviser and Joint Broker with immediate effect. RBC Capital Markets will continue to act as the Company’s Joint Broker.

 

 

-Ends-

 

 

Contact details

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

Nick Keher, Group Chief Financial Officer

Matt Parrish, Head of Investor Relations

 

 

 

J.P.Morgan Cazenove – Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7742 4000

James Mitford / Hemant Kapoor

 

 

 

RBC Capital Markets – Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas

 

 

 

Instinctif Partners

Tel: +44 (0) 20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Phillip Marriage

Email: [email protected]

 

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

 

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

 

For more information on Clinigen, please visit www.clinigengroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 

END

 
 

APPKZGFDLGRGGZM

Leave a Reply

Your email address will not be published.